2,783 results on '"Travis, William"'
Search Results
152. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes
153. Changes in community perspectives on the roles and rules of church forests in northern Ethiopia : evidence from a panel survey of four Ethiopian Orthodox communities
154. Adaptive Neoadjuvant Chemotherapy Guided by 18F-FDG PET in Resectable Non–Small Cell Lung Cancers: The NEOSCAN Trial
155. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
156. The Socialist Challenge Today
157. Histologic Classification and Its Need for Treatment of Lung Cancer
158. Nouvelle classification OMS 2015 des adénocarcinomes pulmonaires et prénéoplasies
159. Pulmonary Myoepithelial Tumors With Exuberant Reactive Pneumocytes: Proposed Reclassification of So-called Pneumocytic Adenomyoepithelioma
160. Defining Morphologic Features of Invasion in Pulmonary Nonmucinous Adenocarcinoma With Lepidic Growth : A Proposal by the International Association for the Study of Lung Cancer Pathology Committee
161. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group
162. Data from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
163. Table S6 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
164. Supplementary Figures from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
165. Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
166. Supplementary Material from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
167. Supplementary Tables from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
168. Supplementary Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
169. Supplementary Data from Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset
170. Supplementary Figure from Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset
171. Data from Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer
172. Supplementary Table 4 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
173. Supplementary Table 5 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
174. Supplementary Table 1 from An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer
175. Supplementary File 6 from Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
176. Supplementary File 2 from Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
177. Data from Prognostic Immune Markers in Non–Small Cell Lung Cancer
178. Supplementary File 1 from Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
179. Supplemental Methods 2 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
180. Supplemental Figure 4 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
181. Supplemental Methods from Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach
182. Supplementary Material from An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer
183. Supplementary Table 6 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
184. Supplementary Figure 1 from Prognostic Immune Markers in Non–Small Cell Lung Cancer
185. Supplementary Figures 1-6 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
186. Supplementary Table 1 from Prognostic Immune Markers in Non–Small Cell Lung Cancer
187. Supplementary File 3 from Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
188. Supplementary Table 1 from Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker
189. Supplementary Figure 3 from Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
190. Supplementary File 5 from Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
191. Supplemental Figure 2 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
192. Figure S1 from Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach
193. Data from Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
194. Supplementary Figure Legend from Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
195. Supplementary Figures from An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer
196. Supplementary Data from Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
197. Table S1 from Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach
198. Supplementary Data from Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung Cancers
199. Supplementary Figure 2 from Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
200. Supplementary File 7 from Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.